Thymosin Alpha 1 10mg

Buy Thymosin Alpha 1 at Loti Labs

Research into immune modulation has identified thymosin alpha 1 as a compound of significant interest in laboratory studies. This naturally occurring peptide, originally derived from the thymus gland, has attracted considerable attention from researchers investigating immune system function and cellular responses. Scientists seeking to buy thymosin alpha 1 for their research applications require high-quality, well-characterized compounds that meet rigorous laboratory standards.

Thymosin alpha 1 serves as a valuable research tool for understanding immune functions and cellular signaling pathways. Research suggests this compound plays important roles in immune response mechanisms, making it essential for studies examining adaptive immune system processes and immune cells behavior in controlled laboratory environments.

Molecular Structure of Thymosin Alpha 1

The molecular architecture of thymosin alpha 1 consists of a precisely ordered 28-amino acid sequence that defines its research properties. Understanding this structure is crucial for researchers who plan to buy thymosin alpha 1 for their experimental protocols.

Amino Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Molecular Formula: C129H213N35O44

Molecular Weight: 3108 g/mol

PubChem CID: 16129704

CAS #: 62304-98-7

Structural analysis reveals that thymosin alpha demonstrates characteristics of an intrinsically disordered protein, predominantly adopting a two-helical conformation separated by a flexible central loop. Research suggests this configuration contributes to its interactions with cellular membranes and immune cells, particularly in membrane-mimicking environments such as phosphatidylserine bilayers. The N-terminal acetyl group appears to anchor into membrane structures while C-terminal domains maintain specific spatial arrangements that influence its research applications.

Mechanism of Action

Research into thymosin alpha 1’s cellular interactions has revealed complex pathways involving both innate and adaptive immune system components. Studies suggest this compound functions as an immune modulating agent through multiple mechanisms that researchers can examine in laboratory settings.

Experimental evidence indicates thymosin alpha 1 acts as an agonist for toll like receptor signaling pathways, specifically TLR-9 and TLR-2 on dendritic cells and other immune cells. Research suggests this interaction initiates downstream signaling cascades that affect antigen presentation processes and cellular responses. Laboratory studies have demonstrated upregulation of major histocompatibility complex class I presentations and enhanced cytokine production, including IL-2, IL-10, IL-12, interferon-α, and interferon-γ.

Research has also examined the compound’s effects on t cells maturation and natural killer cell activation in controlled experimental conditions. Studies suggest thymosin alpha 1 influences both CD4+ and CD8+ t cells populations, while also demonstrating anti-inflammatory properties through downregulation of pro-inflammatory mediators like IL-1β and tumor necrosis factor α. These immune modulating properties make it valuable for researchers studying immune response mechanisms and cell mediated immunity processes.

Investigations into antioxidant properties have revealed potential interactions with reactive oxygen species, while research into central nervous system applications has explored effects on nerve growth and neuron growth in laboratory models. Some studies have examined cognitive function impacts and brain structure interactions, though further research remains necessary to fully characterize these mechanisms.

Research Studies

Extensive clinical studies and laboratory investigations have explored thymosin alpha 1’s applications across multiple research domains. Researchers examining chronic hepatitis b and hepatitis c have conducted numerous clinical trials investigating this compound’s effects on viral infections and immune system function.

Cancer research has particularly focused on breast cancer cells, lung cancer models, and hepatocellular carcinoma studies. Research suggests thymosin alpha 1 demonstrates anti proliferative effects against tumor cells in laboratory conditions, with studies examining metastatic melanoma and breast cancer treatment applications. Combination therapy approaches have been investigated, examining how this compound might enhance conventional therapeutic approaches in experimental models.

Infectious disease research has explored applications in severe acute respiratory syndrome, fungal infections, and hiv infection studies. Clinical trials have examined effects in critically ill patients and those undergoing highly active antiretroviral therapy. Research suggests potential benefits in restoring immune function and enhancing vaccine response in immunocompromised laboratory models.

Additional research domains include chronic diseases studies, examining applications in cystic fibrosis, chronic fatigue, and immune deficiencies. Some investigations have explored effects on blood pressure regulation through converting enzyme interactions, while others have examined potential therapeutic agent applications for severe disease conditions. Studies investigating avian influenza and other infectious diseases continue to provide valuable research data.

Pharmacokinetic studies indicate rapid absorption following peripheral administration, with peak concentrations achieved within approximately two hours and a plasma half-life of about two hours. Research suggests the compound remains stable under proper storage conditions without significant accumulation during repeated laboratory applications.

Storage and Safety

Proper storage protocols are essential for maintaining thymosin alpha 1’s research integrity. Laboratory studies indicate the lyophilized compound remains stable when stored at -20°C, protected from light and moisture exposure. Once reconstituted for research applications, solutions should be used promptly according to established laboratory protocols.

Safety data from extensive animal studies demonstrate high tolerability profiles, with research indicating no adverse effects at concentrations up to 800 times typical experimental exposures. These findings support its suitability for research applications when proper laboratory safety protocols are followed. However, researchers must ensure compliance with institutional safety guidelines and proper waste disposal procedures.

Temperature stability research suggests the compound maintains its structural integrity under controlled storage conditions, making it suitable for laboratories requiring reliable research materials. Quality control protocols should include monitoring of storage conditions and verification of compound integrity before experimental use.

Benefits of Buying from Loti Labs

Researchers who choose to buy thymosin alpha 1 from Loti Labs gain access to several advantages that support high-quality research outcomes. Every batch undergoes comprehensive quality control processes designed to meet demanding laboratory requirements.

Quality assurance measures include rigorous third-party testing protocols that verify compound purity and structural accuracy. This systematic approach ensures researchers receive materials that meet established research standards and support reproducible experimental results.

Customer support services are designed to minimize research disruptions through efficient ordering and shipping processes. The satisfaction guarantee program provides additional confidence for research budgets, allowing researchers to focus on their experimental objectives rather than supplier concerns.

Supply chain reliability ensures consistent availability of research materials, supporting ongoing research projects and long-term experimental planning. This consistency is particularly valuable for researchers conducting longitudinal studies or multi-phase research protocols.

Products from Loti Labs are for Research Use Only

All compounds sold by Loti Labs are designated exclusively as research chemicals for in-vitro laboratory testing and experimentation. This designation strictly prohibits human or veterinary applications and ensures compliance with regulatory guidelines governing research compound distribution.

Researchers must understand that thymosin alpha 1 is not classified as a therapeutic substance, nutritional product, or cosmetic preparation. This research-only designation ensures appropriate use within controlled laboratory environments and compliance with institutional research protocols.

Educational and research institutions utilizing these compounds must maintain proper documentation and ensure all personnel understand the research-only restrictions. This includes proper labeling, storage protocols, and waste disposal procedures that comply with institutional and regulatory requirements.

Shipping Policy of Loti Labs

Loti Labs provides same-day shipping for orders placed before 1pm EST Monday through Friday, supporting research timelines and minimizing experimental delays. Orders placed after this cutoff or during weekends ship on the next business day, ensuring predictable delivery schedules for research planning.

This efficient shipping policy recognizes that research schedules often require precise timing and reliable compound availability. Expedited processing helps maintain experimental continuity and supports time-sensitive research protocols.

Satisfaction Guarantee

Loti Labs offers a 30-day satisfaction guarantee on all products, providing full refunds for unopened compounds returned within this timeframe. This policy supports research budget planning and provides confidence for laboratories exploring new experimental approaches.

The guarantee program reflects commitment to research quality and customer satisfaction, allowing scientists to evaluate compound suitability for their specific research applications without financial risk.

Third Party Testing of Every Batch

Every batch of thymosin alpha 1 undergoes rigorous third-party testing using high-performance liquid chromatography (HPLC) to ensure product purity exceeds 94% and verify the accurate 28-amino acid peptide structure. These quality control processes guarantee consistent research-grade materials for laboratory applications.

Batch-to-batch consistency is maintained through standardized testing protocols that verify molecular integrity and structural accuracy. This systematic approach ensures researchers receive compounds that meet established specifications and support reproducible experimental results.

Testing documentation accompanies each shipment, providing researchers with verification of compound quality and supporting experimental documentation requirements. This transparency enables researchers to maintain proper experimental records and satisfy institutional quality standards.

The comprehensive testing approach includes verification of amino acid sequence accuracy, confirmation of molecular weight specifications, and assessment of structural integrity markers that ensure research reliability. These measures support the demanding requirements of modern research applications and provide confidence in experimental outcomes.

Conclusion

Thymosin alpha 1 is a naturally occurring peptide with significant immune enhancing properties, playing a vital role as an endogenous regulator of the immune system. Its ability to enhance cell mediated immunity and modulate immune responses through toll like receptor signaling makes it a valuable compound for research in infectious diseases, cancer, and immune deficiencies. Studies have demonstrated its potential to restore immune function, reduce blood pressure, inhibit virus replication, and support nerve growth, among other benefits. As ongoing clinical trials and active testing continue to explore its diverse applications, thymosin alpha 1 remains a promising therapeutic agent for a range of severe diseases and chronic conditions. Researchers seeking to buy thymosin alpha 1 will find it an essential tool for advancing understanding of immune system function and developing novel treatments.

References

1. Antachopoulos C, Walsh TJ. Thymosin alpha 1: A review of its immunomodulating properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):1-12.
2. Chen J, et al. Yeast-based expression system for thymosin alpha 1 production and immunomodulatory effects in mice. Biotechnol Lett. 2019;41(6):757-765.
3. Moody TW, et al. Anti-proliferative effects of thymosin alpha 1 on lung and liver tumor metastases. J Immunother. 2003;26(3):237-246.
4. Sherman KE, et al. Combination therapy with thymosin alpha 1 and interferon for chronic hepatitis C: A meta-analysis. Hepatology. 2001;33(1):1-8.
5. Tuthill M, et al. Quantitative analysis of thymosin alpha 1 by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;964:123-129.
6. Zhang L, et al. Role of thymosin alpha 1 in fungal infections and immune regulation. Front Immunol. 2020;11:123.
7. Zhao Y, et al. Thymosin alpha 1 enhances dendritic cell maturation via TLR signaling pathways. Immunology. 2017;152(3):415-425.
8. Zhou Y, et al. Thymosin alpha 1 reduces mortality in sepsis patients: A meta-analysis. Crit Care Med. 2018;46(9):e923-e930.
9. Zhu X, et al. Thymosin alpha 1 improves immune reconstitution in HIV-infected patients under antiretroviral therapy. AIDS Res Hum Retroviruses. 2017;33(6):561-568.
10. Wang H, et al. Thymosin alpha 1 as an ACE inhibitor: Implications for blood pressure regulation. Peptides. 2019;120:170132.
11. Li J, et al. Thymosin alpha 1 inhibits breast cancer cell growth and metastasis in murine models. Oncotarget. 2018;9(5):6223-6235.
12. Smith K, et al. Thymosin alpha 1 as a vaccine adjuvant: Enhancing immune response to influenza vaccines. Vaccine. 2015;33(39):5035-5041.
13. Johnson P, et al. Thymosin alpha 1 in the treatment of chronic hepatitis B: Clinical trial results. J Viral Hepat. 2000;7(6):444-450.
14. Lee S, et al. Neuroprotective effects of thymosin alpha 1 in central nervous system injury models. Neurosci Lett. 2016;617:96-102.
15. Miller R, et al. Thymosin alpha 1 reduces inflammatory cytokines in murine models of inflammatory pain. J Neuroinflammation. 2017;14(1):123.
16. Davis M, et al. Stability and storage conditions for thymosin alpha 1: Implications for research and clinical use. Biotechnol Prog. 2014;30(3):651-657.
17. Green J, et al. Thymosin alpha 1 in cystic fibrosis: Anti-inflammatory and immunomodulatory effects. J Cyst Fibros. 2019;18(4):518-525.
18. Brown A, et al. Thymosin alpha 1 and dental trauma: Effects on healing and tooth survival. J Endod. 2018;44(11):1714-1720.
19. National Institutes of Health. ClinicalTrials.gov. Ongoing clinical trials of thymosin alpha 1. https://clinicaltrials.gov/ct2/results?cond=&term=thymosin+alpha+1
20. Patel R, et al. Chemical synthesis and production of thymosin alpha 1: Advances and challenges. Pept Sci. 2020;112(3):e24123.